Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:16:14.704Z.
Calculation as of: 2026-10-06T14:16:14.704Z.
Quote observation: 2026-10-06T14:11:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fc92921354a3baefe39f76a6e19d16813aeb2294e32cc7e27fab112852b36d76
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Envoy Medical, Inc. (COCH) | $51.72M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.05M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.31M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $50.28M | 9.77 | 4.82 | 27.98 | 18.54 |
| Apollomics, Inc. (APLM)vs › | $52.20M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $50.13M | N/A | 6.87 | 6.87 | 6.87 |
| Clene Inc. (CLNN)vs › | $49.52M | N/A | 13.56 | 13.56 | 13.56 |
| Celularity Inc. (CELU)vs › | $49.49M | N/A | 11.46 | 11.53 | 11.53 |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $54.14M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.67
Forward EPS (Est.)
$-0.29
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2022-03-31 | 135.72 |
| 2022-03-30 | 135.72 |
| 2022-03-29 | 135.72 |
| 2022-03-28 | 135.86 |
| 2022-03-25 | 135.72 |
| 2022-03-24 | 135.72 |
| 2022-03-23 | 135.72 |
| 2022-03-22 | 135.58 |
| 2022-03-21 | 135.58 |
| 2022-03-18 | 135.58 |
| 2022-03-17 | 135.44 |
| 2022-03-16 | 135.58 |
| 2022-03-15 | 135.44 |
| 2022-03-14 | 135.58 |
| 2022-03-11 | 135.44 |
| 2022-03-10 | 135.44 |
| 2022-03-09 | 135.44 |
| 2022-03-08 | 135.16 |
| 2022-03-07 | 135.30 |
| 2022-03-04 | 135.30 |
| 2022-03-03 | 135.30 |
| 2022-03-02 | 135.02 |
| 2022-03-01 | 135.02 |
| 2022-02-28 | 135.02 |
| 2022-02-25 | 134.88 |
| 2022-02-24 | 134.88 |
| 2022-02-23 | 134.74 |
| 2022-02-22 | 134.74 |
| 2022-02-18 | 135.02 |
| 2022-02-17 | 135.02 |
| 2022-02-16 | 135.02 |
| 2022-02-15 | 135.02 |
| 2022-02-14 | 135.02 |
| 2022-02-11 | 134.88 |
| 2022-02-10 | 135.02 |
| 2022-02-09 | 134.61 |
| 2022-02-08 | 134.61 |
| 2022-02-07 | 135.02 |
| 2022-02-04 | 134.61 |
| 2022-02-03 | 135.16 |
| 2022-02-02 | 135.16 |
| 2022-02-01 | 135.16 |
| 2022-01-31 | 134.61 |
| 2022-01-28 | 134.47 |
| 2022-01-27 | 134.61 |
| 2022-01-26 | 134.61 |
| 2022-01-25 | 134.61 |
| 2022-01-24 | 134.74 |
| 2022-01-21 | 134.88 |
| 2022-01-20 | 134.88 |
| 2022-01-19 | 135.30 |
| 2022-01-18 | 135.02 |
| 2022-01-14 | 135.16 |
| 2022-01-13 | 135.16 |
| 2022-01-12 | 135.16 |
| 2022-01-11 | 135.02 |
| 2022-01-10 | 135.58 |
| 2022-01-07 | 135.58 |
| 2022-01-06 | 135.30 |
| 2022-01-05 | 135.44 |
| 2022-01-04 | 135.30 |
| 2022-01-03 | 135.16 |
| 2021-12-31 | 135.30 |